Serum IL-17 levels are higher in critically ill patients with AKI and associated with worse outcomes

Table 3 Multivariable logistic regression of serum IL-17A as the independent variable and (1) hospital mortality and (2) MAKE as the dependent variables

Outcomes	Tertile 1	Tertile 2	Tertile 3	Per onefold higher	Interaction p value^# IL-17A * AKI status
Outcomes	aOR (95% CI)	aOR (95% CI)	aOR (95% CI)	aOR (95% CI)	Interaction p value^# IL-17A * AKI status
IL-17A range, fg/ml	≤ 571.7	586.9–2295.6	≥ 2313.9
No. of patients	99	100	100
Hospital mortality					0.998
No. of death events	9	8	26
Model 1	1.00 (ref)	0.86 (0.30–2.45)	3.48 (1.47–8.25)	1.55 (1.24–1.95)
Model 2	1.00 (ref)	0.82 (0.27–2.48)	2.80 (1.09–7.20)	1.43 (1.12–1.82)
Model 3	1.00 (ref)	0.75 (0.24–2.34)	2.41 (0.92–6.34)	1.35 (1.06–1.73)
MAKE					0.926
No. of MAKE events	21	24	53
Model 1	1.00 (ref)	1.26 (0.63–2.55)	4.31 (2.24–8.32)	1.47 (1.23–1.76)
Model 2	1.00 (ref)	1.21 (0.58–2.52)	3.51 (1.72–7.14)	1.35 (1.19–1.63)
Model 3	1.00 (ref)	1.00 (0.41–2.42)	3.03 (1.34–6.87)	1.26 (1.02–1.55)

MAKE consisted of the composite of death, dependence on renal replacement therapy and eGFR decline ≥ 30% from baseline
Model 1 included age, gender, race, Charlson comorbidity index, and baseline eGFR
Model 2 included variables of Model 1 + non-renal APACHE II and study site
Model 3 included variables of Model 2 + serum creatinine at the time of sample collection (t1)
aOR adjusted odds ratio, MAKE major adverse kidney events at 90 days post-discharge
^#Interaction p value denotes the statistical interaction between IL-17A and AKI status (AKI vs. non-AKI) for the primary study outcomes

ISSN: 1364-8535